Drug Trial Radar · NCT02736955
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Jun 13, 2016
Primary completion
Jun 30, 2017
Study completion Jun 30, 2017
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Apr 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until valbenazine is anticipated to be available commercially or they complete 72 weeks of treatment. This study will allow enrollment of up to 150 medically stable male and female participants with TD who previously participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.
Conditions
- Tardive Dyskinesia
Interventions
ValbenazineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Monitored for Long-term Safety of ValbenazineTime frame: 60 weeks
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Anaheim, California
Site not named
National City, California
Site not named
Norwalk, California
Site not named
Oakland, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Hialeah, Florida
Site not named
North Miami, Florida
Site not named
Orlando, Florida
Site not named
Chicago, Illinois
Site not named
Shreveport, Louisiana
Site not named
Worcester, Massachusetts
Site not named
Cedarhurst, New York
Site not named
Dayton, Ohio
Site not named
Shaker Heights, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Norristown, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Franklin, Tennessee
Site not named
Memphis, Tennessee
Site not named
DeSoto, Texas
Site not named
Fort Worth, Texas
Site not named
Irving, Texas
Site not named
Salt Lake City, Utah
Site not named
Petersburg, Virginia
Site not named
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.